4SC-202 – a promising combination partner for cancer treatment
2017-03-21 · 4SC AG · original 4sc.com ↗
Two poster presentations at the AACR Annual Meeting, 1-5 April 2017, Washington, D.C., USA 4SC-202 plus checkpoint inhibition – boosting the immune system to fight cancer 4SC-202 – a potentially interesting player in acute myeloid leukemia (AML) Planegg-Martinsried, Germany, 21 March 2017 – 4SC AG (4SC, FSE Prime Standard: VSC) today announced that it will present two posters supporting the continued development of its product candidate 4SC-202, an epigenetic modulator with a unique mechanism of action that inhibits both the lysine-specific demethylase (LSD1) protein and class I histone deacetylase proteins (HDAC1, 2, 3), at the upcoming American Association for Cancer Research (AACR) Annual Meeting , being held on 1-5 April 2017 in Washington, D.C., USA. Both posters will be published on 4SC’s website on 3 and 4 April 2017, respectively.
The release as fetched from its publisher. 4sc.com ↗